饲喂益生菌Lactobacillus casei Zhang对高脂日粮大鼠肝脏脂质代谢的作用

doi:10.3864/j.issn.0578-1752.2012.05.015

摘要/Abstract

摘要： 【目的】研究不同剂量益生菌L. casei Zhang（2.0×1010 CFU/d、2.0×109 CFU/d和2.0×108 CFU/d）及其发酵乳饮料（2.0×108 CFU/mL/d）对高胆固醇血症大鼠肝脏脂质的治疗作用。【方法】采用高脂饲料诱导高脂血症，采用相应试剂盒测定肝脏总胆固醇水平（TC）和甘油三酯（TG）水平、粪便总胆汁酸水平与胆固醇水平以及血清载脂蛋白ApoAⅠ与ApoB水平。【结果】益生菌各剂量组和发酵饮料组与高脂模型组相比，肝脏总胆固醇水平（TC）和甘油三酯（TG）水平均显著降低(P＜0.05 或P＜0.01)。各试验组均可显著增加高血脂大鼠粪便总胆汁酸水平和血清载脂蛋白ApoAⅠ水平以及显著降低血清载脂蛋白ApoB水平(P＜0.01)，但对粪便胆固醇水平影响不明显(P＞0.05)。【结论】益生菌L. casei Zhang主要通过增加总胆汁酸的排出和调节载脂蛋白水平来改善高血脂大鼠肝脏脂质水平。

关键词: Lactobacillus casei Zhang, 肝脏脂质, 高血脂大鼠, 总胆汁酸, 载脂蛋白, 粪便胆固醇

Abstract: 【Objective】 The therapeutic effect of different doses of L. casei Zhang (2.0×1010 CFU/d, 2.0×109 CFU/d and 2.0×108 CFU/d) and its fermented milk beverage (2.0×108 CFU/mL/d) on liver lipids of hypercholesterolemia rats was investigated. 【Method】Hypercholesterolemia rats were induced by high fat feeding. Liver TC and TG levels, fecal total bile acid and cholesterol levels as well as serum ApoAⅠand ApoB levels were dertermined by commercial kits. 【Result】 The results showed that liver TC and TG levels were significantly decreased in all probiotic treatment groups compared to hypercholesterolemia model group (P＜0.05 or P＜0.01). In addition, fecal total bile acid levels and serum ApoAⅠlevels were significantly promoted and serum ApoB levels significantly reduced in all probiotic treatment groups compared to model group, while fecal cholesterol levels were changed with no significance (P＞0.05). 【Conclusion】 It is suggested that enhancing elimination of bile acids and regulating apolipoprotein levels could be mainly contributed to liver lipids ameliorated by probiotic L. casei Zhang in hypercholesterolemia rats.

Key words: Lactobacillus casei Zhang, liver lipids, hypercholesterolemia rats, fecal total bile acid level, apolipoprotein, fecal cholesterol level

张勇, 杜瑞亭, 何秋雯, 礼贺, 张和平. 饲喂益生菌Lactobacillus casei Zhang对高脂日粮大鼠肝脏脂质代谢的作用[J]. 中国农业科学, 2012, 45(5): 943-950.

ZHANG Yong, DU Rui-Ting, HE Qiu-Wen, LI He, ZHANG He-Ping. Effect of Lactobacillus casei Zhang Administration on Liver Lipids Metabolism of High-Fat Diet Induced Hypercholesterolemia Rats[J]. Scientia Agricultura Sinica, 2012, 45(5): 943-950.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.chinaagrisci.com/CN/10.3864/j.issn.0578-1752.2012.05.015

https://www.chinaagrisci.com/CN/Y2012/V45/I5/943

参考文献

[1]Cecchini M, Sassi F, Lauer J A, Lee Y Y, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet, 2010, 376(9754): 1775-1784.

[2]Backhed F, Manchester J K, Semenkovich C F, Gordon J L. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proceedings of the National Academy of Sciences of the USA, 2007, 104: 979-984.

[3]Mann G V, Spoerry A. Studies of a surfactant and cholesterolemia in the Maasai. The American Journal of Clinical Nutrition, 1974, 27: 464-469.

[4]Chen Z Y, Jiao R, Ma K Y. Cholesterol-lowering nutraceuticals and functional foods. Journal of Agricultural and Food Chemistry, 2008, 56(19): 8761-8773.

[5]Guo Z, Wang J C, Yan L, Chen W, Liu X M, Zhang H P. In vitro comparation of probiotic properties of Lactobacillus casei Zhang, a potential new probiotic, with selected probiotic strains. Lwt-Food Science and Technology, 2009, 42: 1640-1646.

[6]张和平, 张七斤, 任贵强, 包秋华. 乳酸杆菌对攻毒小鼠的保护作用和对肠道菌群的影响. 微生物学通报, 2007, 34 (3): 447-451.

Zhang H P, Zhang Q J, Ren G Q, Bao Q H. The antagonism of Lactobacillus casei Zhang to pathogenic Escherichia coli in mice and the influence on the microbial population in Gut. Microbiology, 2007, 34(3):447-451. (in Chinese)

[7]Ya T, Zhang Q J, Chu F L, Merritt J, Bilige M H, Sun T S, Du R T, Zhang H P. Immunological evaluation of Lactobacillus casei Zhang:a newly isolated strain fromkoumiss in Inner Mongolia, China. BMC Immunology, 2008(9): 68.

[8]Zhang Y, Du R T, Wang L F, Zhang H P. The antioxidative effects of probiotic Lactobacillus casei Zhang on the hyperlipidemic rats. European Food Research and Technology, 2010, 231(1): 151-158.

[9]托娅, 杜瑞亭, 张和平. 益生菌 L b. casei Zhang 对 H22 荷瘤小鼠的抗肿瘤作用及机制. 肿瘤防治研究, 2010, 37(4):463-465.

Tuo Y, Du R T, Zhang H P. Anti-tumor effect and mechanism of Lb. casei Zhang on H22 tumor-bearing mice. Cancer Research on Prevention and Treatment, 2010, 37(4): 463-465. (in Chinese)

[10]Zhang W Y, Yu D L, Sun Z H, Wu R, Chen X, Chen W, Meng H, Hu S N, Zhang H P. Complete genome sequence of Lactobacillus casei Zhang, a new probiotic strain isolated from traditional home-made koumiss in Inner Mongolia of China. Journal of Bacteriology, 2010, 192(19): 5268-5269.

[11]Wu R, Wang W, Yu D L , Zhang W Y, Li Y, Sun Z H , Wu J, Meng H, Zhang H P. Proteomics analysis of Lactobacillus casei Zhang, a new probiotic bacterium isolated from traditional home-made koumiss in Inner Mongolia of China. Molecular & Cellular Proteomics, 2009, 8(10): 2321-2338.

[12]张和平, 孟和毕力格, 王俊国, 孙天松, 徐杰, 王立平, 云月英, 乌日娜. 分离自内蒙古传统发酵酸马奶中L.casei Zhang潜在益生特性的研究. 中国乳品工业,2006, 34(4)：4-10.

Zhang H P, Bilige M H, Wang J G, Sun T S, Xu J, Wang L P, Yun Y Y, Wu R N. Assessment of potential probiotic properties of L. casei Zhang strain isolated from traditionally home-made Koumiss in Inner Mongolia of China. Chinese Dairy Industry, 2006, 34(4): 4-10. (in Chinese)

[13]云月英, 王立平, 张和平, 陈永福, 孟和毕力格.喂饲Lactobacillus casei Zhang对大鼠体内脂质代谢的影响. 微生物学通报, 2006, 33(3):60-64.

Yun Y Y, Wang L P, Zhang H P, Chen Y F, Bilige M H. Effect of administration of Lactobacillus casei Zhang on serum lipids and fecal steroids in hypercholesterolemic rats. Microbiology, 2006, 33(3): 60-64. (in Chinese)

[14]Kim M, Shin H K. The water soluble extract of chicory influences serum and liver lipid concentration, cecal short-chain fatty acid concentration and fecal lipid excretion in rats. Nutrition, 1998, 128(3):1731-1736.

[15]Fuster V, Voute J, Hunn M, Smith S C Jr. Low priority of cardiovascular and chronic diseases on the global health agenda: a cause for concern. Circulation, 2007, 116(17): 1966-1970.

[16]Jenkins D J, Jones P J, Lamarche B, Kendall C W, Faulkner D, Cermakova L, Gigleux I, Ramprasath V, de Souza R, Ireland C, Patel D, Srichaikul K, Abdulnour S, Bashyam B, Collier C, Hoshizaki S, Josse R G, Leiter L A, Connelly P W, Frohlich J. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. The Journal of the American Medical Association, 2011, 306(8):831-839.

[17]Huang Y, Wang J, Cheng Y, Zheng Y. The hypocholesterolaemic effects of Lactobacillus acidophilus American type culture collection 4356 in rats are mediated by the down-regulation of Niemann-Pick C1-like 1. British Journal of Nutrition, 2010, 104(6):807-812.

[18]Tanida M, Shen J, Maeda K, Horii Y, Yamano T, Fukushima Y, Nagai K. High-fat diet-induced obesity is attenuated by probiotic strain Lactobacillus paracasei ST11 (NCC2461) in rats. Obesity Research & Clinical Practice, 2008, 2(3): 159-169.

[19]Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. Journal of Hepatology, 2008, 49(5):821-830.

[20]Guo Z, Liu X M, Zhang Q X, Shen Z, Tian F W, Zhang H, Sun Z H, Zhang H P, Chen W. Influence of consumption of probiotics on the plasma lipid profile: A meta-analysis of randomised controlled trials. Nutrition, Metabolism & Cardiovascular Diseases, 2011, 21, 844-850.

[21]Turnbaugh P J, Ley R E, Mahowald M A, Magrini V, Mardis E R, Gordon J I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 2006, 444: 1027-1031.

[22]Tuohy K M, Costabile A, Fava F. The gut microbiota in obesity and metabolic disease - a novel therapeutic target. Metabolism Clinical and Experimental, 2009, 27(3): 113-133.

[23]Fukushima M, Yamada A, Endo T, Nakano M. Effects of a mixture of organisms, Lactobacillus acidophilus or Streptococcus faecalis on D6-desaturase activity in the livers of rats fed a fat- and cholesterol- enriched diet. Nutrients, 1999, 15 : 373-378.

[24]Xie N, Cui Y, Yin Y N, Zhao X, Yang J W, Wang ZG, Fu N, Tang Y, Wang X H, Liu X W, Wang C L, Lu F G. Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. BMC Complementary and Alternative Medicine, 2011, 11: 53.

[25]Wang Y, Xu N, Xi A, Ahmed Z, Zhang B, Bai X. Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Applied Microbiology and Biotechnology, 2009, 84(2): 341-347.

[26]Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. European Journal of Clinical Nutrition, 2010, 64(6) :636-634.

[27]Ooi L G, Liong M T. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. International Journal of Molecular Sciences, 2010, 11: 2499-2522.

[28]Jeun J, Kim S, Cho S Y, Jun H J, Park H J, Seo J G, Chung M J, Lee S J. Hypocholesterolemic effects of Lactobacillus plantarum KCTC3928 by increased bile acid excretion in C57BL/6 mice. Nutrition, 2010, 26(3):321-330.

[29]Begley M, Hill C, Gahan C G. Bile salt hydrolase activity in probiotics. Applied and Environmental Microbiology, 2006, 72(3):1729-1738.

[30]Zhang W Y, Wu R, Sun Z H, Sun TS, Meng H, Zhang H P. Molecular cloning and characterization of bile salt hydrolase in Lactobacillus casei Zhang. Annals of Microbiology, 2009, 59(4) :1-6.

[31]Sridevi N, Vishwe P, Prabhune A. Hypocholesteremic effect of bile salt hydrolase from Lactobacillus buchneri ATCC 4005. Food Research International, 2009, 42(4): 516-520.

[32]Collado M C, Meriluoto J, Salminen S. Adhesion and aggregation properties of probiotic and pathogen strains. European Food Research and Technology, 2008, 226:1065-1073.

[33]Yin Y N, Yu Q F, Fu N, Liu X W, Lu F G. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World Journal of Gastroenterology, 2010, 16(27):3394-3401.

[34]Rauchhaus M, Coats A J, Anker S D. The endotoxin-lipoprotein hypothesis. Lancet, 2000, 356: 930-933.

[35]Vreugdenhil A C, Snoek A M, van't Veer C, Greve M J W, Buurman W A. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. The Journal of Clinical Investigation, 2001, 107: 225-234.

[36]Cani P D, Amar J, Iglesias M A, Poggi M, Knauf C, Bastelica D, Neyrinck A M, Fava F, Tuohy K M, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti J F, Gibson G R, Casteilla L, Delzenne N M, Alessi M C, Burcelin R.Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 2007, 56(7): 1761-1772.

[37]Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. Journal of Applied Microbiology, 2011, 110(3): 650-657.

[38]Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal of Internal Medicine, 2004, 255(2):188-205.